🔗 Share this article

As the United States proceeds with unprecedented adjustments to its vaccine guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning COVID-19 shots throughout the pandemic and has zeroed in on possible deaths after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Public health authorities were set to unveil radical revisions to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of alignment with many the world with no evidence for public health gain. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Dr. Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to run the center this year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the drug and biologics branches as Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a nation with nationalized medicine and a population approximately the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in medication creation, regulation or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have any of the qualifications” for leading the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous heads of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who ran CBER have had.”

This division has an immense portfolio at the FDA, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and all of those need to be looked after,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative element to the job, which oversees more than 5,000 staff members. “It is a huge leadership role, if you do it right,” she concluded.

Agency Reaction and Controversial Programs

When asked about concerns about Høeg’s fitness for the role and whether this selection represents more teamwork among agency officials on vaccines, a representative said that the “inquiries rely on inaccurate assumptions”.

“Her resume aligns with the duties of her position,” the official explained, noting the months Høeg spent advising the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a controversial expedited medication authorization process that apparently worried her preceding directors. “By what process are these medications being chosen for this voucher program? Who makes the calls?” Dr. Howard said. “There’s a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards laxer regulations of all drugs, aside from shots.”

Documented Track Record on Immunizations

With immunizations, Dr. Høeg has a more documented, if troubling, track record, critics observe. She published a analysis using unverified public submissions to determine the incidence of myocarditis after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the incoming federal leadership encompassed revising guidelines for recently developed shots and ending “unnecessary” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has allegedly proposed barring teenage boys from receiving Covid vaccines.

“She’s an thorough ideologue who commences with her conclusions and works backwards to retrofit the data in a very misleading, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|